Nevotens (Nebivolol Hydrochloride)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. It also stimulates endothelial nitric‑oxide synthase, causing nitric‑oxide release that dilates peripheral blood vessels. This dual action lowers blood pressure and reduces cardiac workload.

The appropriate dose of Nevotens is determined by a qualified prescriber based on the individual’s clinical condition, age, renal function and response to therapy. Typical dosing ranges are described in the prescribing information, but the exact regimen should be set by the treating physician.

Safety data for nebivolol during pregnancy and lactation are limited. The product is classified as a pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider before use.

To request Nevotens, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nevotens (nebivolol) is a highly selective β1‑blocker that also promotes nitric‑oxide mediated vasodilation, offering a favorable profile for blood‑pressure reduction with fewer bronchoconstrictive effects compared with non‑selective beta‑blockers. This dual mechanism can provide better tolerability in some patients.

Nevotens tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Nevotens is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and whether the dose should be taken in the morning or evening.

Serious adverse reactions to Nevotens include severe bradycardia, symptomatic hypotension and bronchospasm, especially in patients with pre‑existing respiratory disease. Prompt medical attention is required if these symptoms occur.

Nevotens should be avoided in patients with known hypersensitivity to nebivolol or any excipients, in those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and in individuals with uncompensated heart failure or severe hepatic impairment unless specifically advised by a physician.